A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2006
10/25/2006	EP1713917A2 Pneumolysin derivatives
10/25/2006	EP1713907A2 Hybrid proteins of active-site serine beta-lactamase.
10/25/2006	EP1713902A1 Live attenuated salmonella for use as vaccine
10/25/2006	EP1713830A2 Anti-epcam immunoglobulins
10/25/2006	EP1713824A2 Recombinant viruses with heterologous envelope proteins
10/25/2006	EP1713503A1 Inhibition of factor b, the alternative complement pathway and methods related thereto
10/25/2006	EP1713502A1 Highly concentrated liquid formulations of anti-egfr antibodies
10/25/2006	EP1713501A1 Treatment of neurodegenerative diseases by the use of gpr49
10/25/2006	EP1713495A2 Method of inducing or modulating immune response
10/25/2006	EP1713472A2 Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
10/25/2006	EP1713441A2 Interleukin-13 antagonist powders, spray-dried particles, and methods
10/25/2006	EP1495767B1 Immunoadjuvant
10/25/2006	EP1423417B1 Antibodies recognizing a peptide mimicking a cryptic epitope of gp41 of hiv-1
10/25/2006	EP1401496B1 Compositions and methods for treating hyperimmune response in the eye
10/25/2006	EP1377275B1 Vaccine for modulating between t1 and t2 immune responses
10/25/2006	EP1373308B1 Antagonist for multimerization of hiv-1 vif protein
10/25/2006	EP1332155B1 Immunization of dairy cattle with gapc protein against streptococcus infection
10/25/2006	EP1292615B1 Modified morbillivirus v proteins
10/25/2006	EP1109901B1 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF
10/25/2006	EP1107993B1 Human monoclonal antibodies directed against the islet cell antigen ia-2
10/25/2006	EP0983088B1 Immunpotentiating composition in a solid dosage form, having collagen or polydimethylsiloxane as a carrier substance
10/25/2006	EP0973802B1 Synthetic peptides useful in biological assays for detecting infections caused by group o hiv-1 viruses
10/25/2006	CN1852981A The anti-platelet membrane glycoprotein VI monoclonal antibody
10/25/2006	CN1852976A Binding constructs and methods for use thereof
10/25/2006	CN1852923A Human antibody molecules for IL-13
10/25/2006	CN1852921A Soluble fragments of the SARS-cov spike glycoprotein
10/25/2006	CN1852737A Combination of a histone deacetylase inhibitor with a death receptor ligand
10/25/2006	CN1852736A Immunoglobulin chimeric monomer-dimer hybrids
10/25/2006	CN1852735A Vaccine formulations comprising an oil-in-water emulsion
10/25/2006	CN1852734A Consensus/ancestral immunogens
10/25/2006	CN1852733A Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
10/25/2006	CN1852730A Modulators of P-selectin glycoprotein ligand 1
10/25/2006	CN1852727A Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
10/25/2006	CN1852701A Method and apparatus for preventing allergies
10/25/2006	CN1852690A Medicament conveying system
10/25/2006	CN1851461A Pharmaceutical use of heat shock protein 27 for serological identification and liver cancer diagnosis
10/25/2006	CN1850861A Anti white spot virus adherent protein VP19 monocloral antibody, and its preparing method
10/25/2006	CN1850860A Antifish lymphocystis virus capsid protein monoclonal antibody, and its preparing method
10/25/2006	CN1281758C Eukaryotic expression vector of ER-detented IV collagenase cellular antibody gene
10/25/2006	CN1281753C Monoclonal antibody CAb-1 heavy and light chain variable region gene of human carcinoma of large intestine, and its uses
10/25/2006	CN1281748C Gene of IL-12 p40 subunit mutated for improving activity of IL-12 and use thereof for DNA vaccine adjuvant
10/25/2006	CN1281747C i(Ehrlichia canis) 120-KDa immunodominant antigenic protein and gene
10/25/2006	CN1281625C WT1 modified peptide
10/25/2006	CN1281277C DNA vaccine for preventing influenza virus infection
10/25/2006	CN1281273C Debilitating agent for highly toxic chicken coccidian and its preparation
10/24/2006	US7125964 Using magnetic beads conjugated with major histocompatability complex peptides to purify and expand in vitro tumor- and virus-specific killer lymphocytes for use in cell therapy, tissue targeted therapy and engineering
10/24/2006	US7125958 membrane proteins acting as binding ligands to mucopolysaccharide receptors for antigens present on the surfaces of palsmodium infected erythrocytes; drugs; antibodies
10/24/2006	US7125860 Cross-linked derivatives of hyaluronic acid
10/24/2006	US7125837 Elastin-based compositions
10/24/2006	US7125836 Method of cancer screening; method of cancer treatment; and method of diabetes treatment
10/24/2006	US7125720 live vector vaccine; removal of sole dependence on catalytic balanced lethal maintenance systems; plasmid partition system prevents random segregation; enhanced inheritance and stability; genetic engineering; antibiotic resistance
10/24/2006	US7125718 Method for introducing and expressing genes in animal cells, and bacterial blebs for use in same
10/24/2006	US7125714 Progenitor cell materials and methods
10/24/2006	US7125712 DNA segment from a BIV genome; a packaging sequence to package RNA into virions; a first promoter operably linked to the DNA segment; d) a transgene operably linked to a second promoter and deletion of vpw, vpy and tat from the construct
10/24/2006	US7125706 Method for the production and purification of adenoviral vectors
10/24/2006	US7125696 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
10/24/2006	US7125689 Method for rendering streptokinase less immunogenic to a human
10/24/2006	US7125675 Method for inhibiting tumor invasion or spreading in a subject
10/24/2006	US7125670 Comprises activated CD4 T-cells (ACT-4-L) ligand polypeptide for detection of immunomodulators; autoimmune diseases; drug screening; immunosuppressants; viricides
10/24/2006	US7125568 Lipophilic drug compositions
10/24/2006	US7125557 Isolated haemocyanin polypeptide having a specific amino acid sequence recombinantly expressed in a host cell, wherein the glycosylation pattern is different from naturally occurring KLH from Megathura crenulata; may be bonded to a virus, bacteria, DNA, carbohydrate, peptide or glycoprotein
10/24/2006	US7125556 Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin
10/24/2006	US7125554 Engineered superantigen for human therapy
10/24/2006	US7125553 Inhibiting a rejection response to foreign mammalian donor cells, tissue or organ by administering an sFv-DT390 anti-CD3-DT immunotoxin; optionally administering an immunosuppressant such as a cyclosporin, mycophenolate mofetil or deoxyspergualin; and effecting transplantation
10/24/2006	US7125552 Glycine extraction of a water and ethanol suspension of the immunoglobulins, followed by anion exchange chromatography to achieve a significantly high yield and high purity
10/24/2006	US7125551 Compound for use inthe diagnosis and treatment of cancer, viral, asthmatic, autoimmune, organ transplant rejection and infections
10/24/2006	US7125550 Play a role in capacitation of sperm and the fertilization of the ovum and make ideal targets for the design of contraceptive agents.
10/24/2006	US7125548 Nucleotide sequences coding microorganismal cistron; for use in detection of microoganismal infection
10/24/2006	US7125544 First product containing an enzyme (particularly papain) and a lactate, glycolate, thioglycolate or salicylate of monoethanolamine that is separate from and administered before a second product containing an oxidizer (e.g., sodium bromate)
10/24/2006	US7125542 Methods and compositions for treating conditions of the eye
10/24/2006	US7125541 Administering targeting agent operatively attached to a therapeutic agent, and wherein the targeting agent recognizes and binds to a tumor-associated endothelial cell marker
10/24/2006	CA2342948C Attenuated vaccine for blastomyces dermatitidis
10/19/2006	WO2006110915A2 Vaccine formulations for leishmania
10/19/2006	WO2006110831A2 Method of inducing neutralizing antibodies to human immunodeficiency virus
10/19/2006	WO2006110760A2 Compositions and methods for the diagnosis and treatment of tumor
10/19/2006	WO2006110748A2 Response gene to complement 32 (rgc-32) in disease
10/19/2006	WO2006110728A2 Immunogenic cmv tegument aggregates
10/19/2006	WO2006110623A2 Targeted cholera toxin for treatment of persistent or chonic pain
10/19/2006	WO2006110603A1 Stabilization and preservation of temperature-sensitive vaccines
10/19/2006	WO2006110594A2 Sema4d in cancer diagnosis, detection and treatment
10/19/2006	WO2006110381A1 Multivalent pneumococcal polysaccharide-protein conjugate composition
10/19/2006	WO2006110344A1 Novel methods for inducing an immune response against human immunodefiency virus
10/19/2006	WO2006110214A2 Antibodies against mammalian metapneumovirus
10/19/2006	WO2006110164A2 Deactivation of linking moieties in antibody-enzyme conjugates
10/19/2006	WO2006110132A1 Methods and compositions for mycoplasma pneumoniae exotoxins
10/19/2006	WO2006109592A1 Antibody substituting for function of blood coagulation factor viii
10/19/2006	WO2006109300A1 Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
10/19/2006	WO2006109286A1 Filamentous hemagglutinin for the prevention of the development of neutralising antibodies to a biologic agent
10/19/2006	WO2006109285A1 Methods and compounds for the treatment of autoimmune diseases and chronic inflammatory conditions
10/19/2006	WO2006109195A2 Modulation of an immune response by filamentous haemagglutinin
10/19/2006	WO2006109188A2 Composition for treating cancer adapted for intra-tumoral asministration and uses thereof
10/19/2006	WO2006109186A2 Early endosome neutralising compouds as vaccine adjuvants
10/19/2006	WO2006109071A2 Vaccine against burkholderia infections
10/19/2006	WO2006109045A2 Cathepsin s antibody
10/19/2006	WO2006109044A2 Selective modulation of tumour necrosis factor receptors in therapy
10/19/2006	WO2006108846A1 Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
10/19/2006	WO2006108763A1 Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
10/19/2006	WO2006108670A2 Use of cd25 antibodies in immunotherapy
10/19/2006	WO2006108574A1 Method for the delivery of exogenous antigens into the mhc class i presentation pathway of cells
10/19/2006	WO2006108241A1 Immunomodulating compositions and uses therefor

1 ... 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 ... 1823